Raymond James Financial Inc. bought a new position in shares of Glaukos Co. (NYSE:GKOS - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 112,771 shares of the medical instruments supplier's stock, valued at approximately $16,910,000. Raymond James Financial Inc. owned 0.20% of Glaukos at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. IFP Advisors Inc bought a new position in shares of Glaukos during the fourth quarter worth $43,000. Asset Planning Inc bought a new stake in Glaukos in the 4th quarter valued at $90,000. Harvest Fund Management Co. Ltd increased its holdings in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock worth $117,000 after purchasing an additional 860 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Glaukos in the fourth quarter valued at about $153,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock worth $164,000 after buying an additional 807 shares during the period. 99.04% of the stock is owned by institutional investors.
Insider Buying and Selling
In other news, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.40% of the stock is owned by insiders.
Glaukos Stock Performance
Shares of GKOS traded up $1.39 during trading hours on Friday, hitting $102.02. The company had a trading volume of 1,021,766 shares, compared to its average volume of 585,887. The firm has a market cap of $5.77 billion, a price-to-earnings ratio of -35.55 and a beta of 0.99. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The business has a fifty day moving average of $136.42 and a 200-day moving average of $136.75. Glaukos Co. has a 12 month low of $86.74 and a 12 month high of $163.71.
Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Equities analysts anticipate that Glaukos Co. will post -1.08 EPS for the current fiscal year.
Analyst Ratings Changes
GKOS has been the topic of several research reports. Needham & Company LLC boosted their target price on Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Stifel Nicolaus lifted their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research note on Tuesday, December 31st. Truist Financial boosted their price target on shares of Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Mizuho raised Glaukos from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $140.00 to $200.00 in a research report on Wednesday, February 19th. Finally, Stephens upgraded Glaukos to a "strong-buy" rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $163.25.
Check Out Our Latest Analysis on GKOS
About Glaukos
(
Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Read More
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
